Biogen makes up to $1B deal for secretive anti-inflammatory biotech — Live Feedhttps://www.live-feeds.com/feed/biogen-makes-up-to-1b-deal-for-secretive-anti-inflammatory-biotechContinuously updated, source-cited coverage. Biogen acquires RayThera in deal worth up to $1 billionhttps://www.live-feeds.com/feed/biogen-makes-up-to-1b-deal-for-secretive-anti-inflammatory-biotechhttps://www.live-feeds.com/feed/biogen-makes-up-to-1b-deal-for-secretive-anti-inflammatory-biotech#u13283Thu, 25 Jun 2026 20:41:44 +0000Biogen is buying San Diego-based RayThera to expand its immunology pipeline. The deal adds three preclinical anti-inflammatory assets. The total value of the acquisition is up to $1 billion.What's confirmed:Biogen agreed to acquire RayThera for up to $1 billion.The acquisition adds three preclinical anti-inflammatory assets to Biogen's immunology pipeline.Still unconfirmed:The assets acquired from RayThera are small-molecule anti-inflammatories.Biogen is pivoting toward partnerships. Biogen to Acquire RayThera for Up to $1 Billionhttps://www.live-feeds.com/feed/biogen-makes-up-to-1b-deal-for-secretive-anti-inflammatory-biotechhttps://www.live-feeds.com/feed/biogen-makes-up-to-1b-deal-for-secretive-anti-inflammatory-biotech#u8948Mon, 22 Jun 2026 23:15:57 +0000Biogen is acquiring San Diego-based RayThera to grow its immunology pipeline. The deal includes three preclinical anti-inflammatory assets. Payment consists of an upfront sum and milestones linked to regulatory and clinical success.What's confirmed:Biogen is acquiring RayThera for up to $1 billion.The acquisition adds three preclinical anti-inflammatory assets to Biogen's pipeline.The deal involves an upfront payment and milestone payments based on clinical and regulatory success. Biogen Agrees to Acquire RayThera for Up to $1 Billionhttps://www.live-feeds.com/feed/biogen-makes-up-to-1b-deal-for-secretive-anti-inflammatory-biotechhttps://www.live-feeds.com/feed/biogen-makes-up-to-1b-deal-for-secretive-anti-inflammatory-biotech#u5042Fri, 19 Jun 2026 21:06:36 +0000Biogen has reached an agreement to buy San Diego-based RayThera to expand its immunology pipeline. The deal provides Biogen with three preclinical small-molecule anti-inflammatory assets. A lead candidate is expected to enter Phase 1 clinical development in early Q3 2026.What's confirmed:Biogen agreed to acquire RayThera for up to $1 billion.The acquisition includes three preclinical anti-inflammatory programs.RayThera is based in San Diego.The lead candidate is slated for Phase 1 development in early Q3 2026.The deal consists of an upfront cash payment and contingent milestone payments.Comple